Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress

T. Kato, H. Satake, K. Oba, Y. Kagawa, H. Yasui, M. Nakamura, T. Watanabe, T. Matsumoto, K. Hirata, K. Muro, Y. Komatsu, T. Yoshino, K. Yamazaki, H. Mishima, M. Kotaka, A. Tsuji, Y. Kakeji, E. Oki, N. Nagata, J. Sakamoto

Research output: Contribution to journalArticle

12 Citations (Scopus)
Original languageEnglish
Pages (from-to)v83
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume29
DOIs
Publication statusPublished - Jun 1 2018

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Kato, T., Satake, H., Oba, K., Kagawa, Y., Yasui, H., Nakamura, M., Watanabe, T., Matsumoto, T., Hirata, K., Muro, K., Komatsu, Y., Yoshino, T., Yamazaki, K., Mishima, H., Kotaka, M., Tsuji, A., Kakeji, Y., Oki, E., Nagata, N., & Sakamoto, J. (2018). Multicenter phase Ib/II study of biweekly TAS-102 with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study) - Trial in progress. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v83. https://doi.org/10.1093/annonc/mdy151.293